Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis

详细信息    查看全文

• 作者：Jia-Horng Kao ; Shui-Yi Tung ; Younjae Lee ; Satawat Thongsawat ; Tawesak Tanwandee ; I.-Shyan Sheen ; Jinzi J. Wu ; Hui Li ; Barbara J. Brennan ; Julian Zhou ; Sophie Le Pogam ; Isabel Najera ; James A. Thommes and George Hill
• 刊名：Journal of Gastroenterology and Hepatology
• 出版年：2016
• 出版时间：October 2016
• 年：2016
• 卷：31
• 期：10
• 页码：1757-1765
• 全文大小：404K
• ISSN：1440-1746

文摘

Chronic hepatitis C is an important public health problem in Asia. We evaluated the safety, efficacy, and pharmacokinetics of fixed-dose ritonavir-boosted danoprevir plus peginterferon alfa-2a/ribavirin in treatment-naive Asian patients with chronic hepatitis C virus (HCV) genotype (G)1 infection.